



Published in final edited form as:

*S Afr Respir J*. 2017 ; 23(4): 106–112.

## Predictors and short-term outcomes of recurrent pulmonary tuberculosis, Uganda: a cohort study

Nelson Kalema<sup>1,2</sup>, Christina Lindan<sup>3</sup>, Dave Glidden<sup>3</sup>, Samuel D. Yoo<sup>1,4</sup>, Achilles Katamba<sup>2</sup>, Andama Alfred<sup>1</sup>, Wincelous Katagira<sup>1</sup>, Patrick Byanyima<sup>1</sup>, Emmanuel Musisi<sup>1</sup>, Sylvia Kaswabuli<sup>1</sup>, Sanyu Ingvar<sup>1</sup>, Josephine Zawedde<sup>1</sup>, Christina Yoon<sup>1,5</sup>, Irene Ayakaka<sup>1</sup>, J. Lucian Davis<sup>7,8</sup>, Laurence Huang<sup>1,5,6</sup>, William Worodria<sup>1,2</sup>, and Adithya Cattamanchi<sup>1,3,5</sup>

<sup>1</sup>Infectious Disease Research Collaboration, Kampala, Uganda <sup>2</sup>Department of Medicine, Mulago Hospital, Makerere University, Kampala, Uganda <sup>3</sup>Department of Epidemiology and Biostatistics and Global Health Sciences, University of California San Francisco, San Francisco, CA <sup>4</sup>Department of Internal Medicine, Jimma University, Jimma, Ethiopia <sup>5</sup>Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA <sup>6</sup>HIV, Infectious Diseases, and Global Medicine Division, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, CA <sup>7</sup>Yale School of Public Health, New Haven, CT <sup>8</sup>Pulmonary, Critical Care, and Sleep Medicine Section, Yale School of Medicine, New Haven, CT

### Abstract

**Introduction**—Recurrent tuberculosis (TB) occurring >2 years after completing treatment for a prior TB episode is most often due to reinfection with a new strain of *M. tuberculosis*.

**Objectives**—We determined the prevalence and outcome of late recurrent TB among hospitalized patients in Kampala, Uganda.

**Methods**—We conducted a retrospective analysis of patients admitted to Mulago Hospital who had cough of >2 weeks' duration and completed TB treatment >2 years prior to admission. All patients had mycobacterial culture performed on two sputum specimens and vital status ascertained 2-months post-enrollment. We performed logistic regression and Cox proportional hazards modelling to identify predictors of recurrent TB and survival, respectively.

**Results**—Among 234 patients, 84 (36%) had recurrent TB. Independent predictors included younger age (aOR=0.64, 95% CI=0.42-0.97, p=0.04), chest pain >2 weeks (aOR=3.32, 95%

---

Corresponding author: Nelson Kalema, MBChB, M. Med, Clinical Research Scholar, MAS Program UCSF, C/O Makerere University College of Health Sciences, Implementation Science Program, P. O Box 7072, Kampala Uganda, kalemanelson@gmail.com, Phone: +256782313109.

#### Author Contributions

Conceived and designed the experiments: NK WW AK AI JLD SDY LH AC.

Performed the experiments: SK EM PB AA.

Analyzed the data: NK DG AC JLD LH.

Contributed reagents/materials/analysis tools: LH AC JLD

Wrote the paper: NK DG KL SDY LH JLD WW AC.

Enrolled and cared for the patients included in this study: KW, NK, ZJ, SI.

Conflicts of interest: None

CI=1.38-8.02,  $p=0.007$ ), severe weight loss  $\geq 5$  kilograms (aOR=4.88, 95% CI=1.66-14.29,  $p=0.004$ ) and presence of  $\geq 1$  WHO danger sign of severe illness (aOR=3.55, 95% CI=1.36-9.29,  $p=0.01$ ). Two-month mortality was 17.8% (95% CI=10.5-29.2%), and was higher among patients who were not initiated on TB treatment (aHR=16.67, 95% CI=1.18-200,  $p=0.04$ ), those who were HIV-positive and not on antiretroviral treatment (aHR=16.99, 95% CI=1.17-246.47,  $p=0.04$ ) and those with a history of smoking (aHR=1.20, 95% CI=1.03-1.40,  $p=0.02$ ).

**Conclusion**—The high prevalence of late recurrent TB likely reflects high levels of TB transmission in Kampala. Increased use of empiric TB treatment and early ART treatment initiation if HIV-positive should be considered in patients with a prior history of TB, particularly if they are young, with weight loss  $\geq 5$  kgs, chest pain  $>2$  weeks or  $\geq 1$  WHO danger sign of severe illness.

### Keywords

Recurrent TB; survival; treatment; Africa; Uganda

## INTRODUCTION

Recurrence of tuberculosis (TB) following completion of treatment is an important but understudied problem in high-burden countries.<sup>[1-3]</sup> Recurrent TB can result from relapse of the original *M. tuberculosis* strain or from reinfection with a new strain.<sup>[4]</sup> Relapse usually occurs because of inadequate treatment whereas reinfection reflects high rates of ongoing TB transmission in at risk populations.<sup>[3, 5]</sup> Data show that the risk of recurrent TB due to reinfection is higher among HIV-positive than HIV-negative persons.<sup>[6]</sup> Thus, assessing the burden of recurrent TB and its causes in high TB-HIV incidence settings can help TB control programs determine whether limited additional resources should be focused on enhanced treatment monitoring and adherence to reduce relapse, or on TB case finding and treatment to interrupt transmission.

Molecular genotyping is the gold standard for assessing whether recurrent TB is due to relapse versus reinfection. Unfortunately, however, only a few studies in high TB burden settings have described the burden of recurrent pulmonary TB using molecular genotyping. These studies indicate that the length of time between completion of treatment and recurrence is indicative of whether recurrent disease is a result of re-infection or relapse. A study in southern India found that among patients who developed recurrent pulmonary TB one to two years following completion of treatment, the recurrence was due to relapse in 91% of HIV-uninfected patients, and was due to reinfection in 88% of HIV-infected patients.<sup>[7]</sup> In Uganda, relapse was determined to be the cause of recurrence in 80 of 98 (82%) patients presenting with another episode of TB one to two years following treatment of prior disease.<sup>[8]</sup> In contrast, among patients who developed recurrent TB  $> 2$  years after treatment completion, molecular genotyping studies have shown reinfection to be the predominant cause.<sup>[9]</sup> In Cape Town, South Africa, a study in a predominantly HIV-uninfected population found that reinfection accounted for 12/16 (75%) cases of recurrent TB.<sup>[10]</sup> Similarly, another study from South Africa found that reinfection accounted for 23/66 (34%) recurrent TB episodes among patients who completed treatment within the prior two years but for 43/66 (65%) of recurrent TB episodes among patients who had completed treatment  $> 2$

years earlier.<sup>[11]</sup> Studies from low-burden settings where re-infection is less likely to occur, have found that greater than 90% of relapses develop within two years of treatment completion, a key reason why Phase 3 trials of novel anti-TB drugs or regimens limit follow-up to 2 years.<sup>[12]</sup> Thus, assessing TB recurrence among patients who completed treatment for an episode of TB > 2 years earlier can serve as a proxy for reinfection.

Few studies have assessed the burden and outcome of reinfection in East Africa. Therefore, we assessed the prevalence of late recurrent pulmonary TB among hospitalized patients in Kampala, Uganda. In addition, we identified predictors and short-term mortality of late recurrent TB.

## METHODS

### Study design

We performed a secondary data analysis of data collected on a cohort of patients who were admitted with presumed pneumonia to Mulago Hospital in Kampala, Uganda from October 2008 to December 2013. The parent study, called the International HIV-associated Opportunistic Infections (IHOP) study, has been described in detail previously.<sup>[13-15]</sup> Briefly, IHOP was a prospective study of consecutive adults 18 years of age admitted to Mulago Hospital with a history of unexplained cough of two weeks' to six months' duration. Patients who had been on TB treatment within the last two years or had evidence of heart failure were excluded. At the time of enrollment, patients completed a questionnaire on demographics and clinical history. HIV testing was performed using the Ugandan Ministry of Health-approved sequential HIV-antibody testing algorithm that incorporates three rapid enzyme immunoassay kits, and CD4 cell counts were measured among those who were HIV seropositive. Smear microscopy and Lowenstein-Jensen culture were performed on two sputum samples (spot and early morning) for detection of TB. In addition, Xpert MTB/RIF testing was performed on sputum samples of patients enrolled after August 2009, and on banked sputum sediment for study participants enrolled between October 2008 and August 2009 before Xpert MTB/RIF testing was available. Test results were provided to ward clinicians who made all treatment decisions. Study staff scheduled patients for in-person follow-up at two weeks, one month and two months after enrollment to ascertain vital status, and to determine whether anti-TB and/or anti-retroviral treatment (ART) had been initiated. Study staff contacted patients or their nominated next of kin by phone to ascertain TB treatment and vital status if a follow-up visit was missed.

The parent study was approved by the institutional review boards of the University of California, San Francisco, Makerere University School of Medicine, and Mulago Hospital, as well as by the Uganda National Council for Science and Technology. All participants provided informed written consent.

For this study, we evaluated data on all patients who reported completing treatment for drug-susceptible TB >2 years prior to study enrolment. We also re-contacted patients or their next of kin to ascertain their vital status at 60 days, if this information was missing.

## Outcome definitions

The primary study outcome was culture-confirmed late recurrent pulmonary TB. Patients were considered to have late recurrent TB if one or more sputum culture results were positive and confirmed by speciation testing to be *M. tuberculosis*. Patients who had contaminated or missing cultures were excluded from the analysis (Figure 1). The secondary study outcome was mortality at 60 days after enrollment.

## Statistical analyses

We compared baseline demographic and clinical characteristics between patients with and without late recurrent TB using the chi-squared test for dichotomous variables and the Mann-Whitney rank sum test for continuous variables. We performed univariate logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association of baseline patient characteristics with late recurrent TB; variables associated with the outcome at a  $p < 0.1$  were considered for inclusion in a multivariable model.<sup>[2, 16-18]</sup> Likelihood ratio testing (LRT) was used for model building and the goodness of fit test was used to assess the model fit. To determine cumulative 2-month mortality, we performed Kaplan-Meier survival analysis and log-rank tests of equality across strata for categorical predictors. Cox-proportional hazards modeling was used to identify clinical factors associated with two-month mortality. We included *a priori* known risk factors for TB-related mortality, including age, gender, history of smoking, World Health Organization (WHO) danger signs of severe illness (temperature  $> 39$  degrees Celsius, a respiratory rate  $> 30$  breaths per minute, a heart rate  $> 120$  beats per minute, and being non-ambulatory because of illness),<sup>[19]</sup> HIV infection, ART and anti-TB treatment.<sup>[20-24]</sup> Likelihood ratio testing (LRT) was used for model building and the goodness of fit test to assess model fit. Cox proportional hazards assumptions were tested using the method of Schoenfeld residuals and determined to meet assumptions ( $p > 0.05$ ). The c-statistic was calculated as a standard summary measure of model performance.<sup>[25]</sup>

## RESULTS

### Study population

2,650 patients were enrolled into the parent IHOP study, of whom 260 had a previous history of TB and had completed treatment more than two years previously; 26 patients were excluded because of contaminated cultures (N=24) or lack of culture results (N=2). Thus, we present data on 234 patients (Figure 1). The median age was 36.9 yrs (IQR:30.8-44.2) and 58.6% were male (Table 1). The majority (68.8%) were HIV sero-positive among whom the median CD4 count was 119 (22-304) cells/uL; 46.6% were on ART at study enrolment. More than half (61.6%) had 1 WHO severe illness danger signs.

### Prevalence and diagnosis of late recurrent TB

Overall, 84 (35.9%) patients had culture-confirmed late recurrent TB. Smear microscopy results were available for 226/234 (96.6%) and Xpert MTB/RIF results for 224/234 (95.7%) patients. Using culture results as the gold standard, compared to sputum smear microscopy, Xpert MTB/RIF had higher sensitivity (78.6%, 95% CI 68.3-86.8 vs. 65.8%, 95% CI

54.3-76.1; McNemar's  $X^2$  test;  $p=0.0124$  but similar specificity (96.4%, 95% CI 91.9-98.8 vs. 95.9%, 95% CI 91.3-98.5. McNemar's  $X^2$  exact test;  $p=1.000$ ). Xpert MTB/RIF identified rifampin resistance in 3/84 (3.6%) patients with culture-confirmed late recurrent TB.

### Demographic and clinical predictors of late recurrent TB

Compared to patients without late recurrent TB, patients with culture-confirmed late recurrent pulmonary TB were more likely to report severe weight loss  $\geq 5$  kilograms (75.3% vs. 55.7%,  $p=0.004$ ), have chest pain  $\geq 2$  weeks (77.2% vs. 46.0%,  $p<0.001$ ), have a lower CD4 count if HIV-positive (70 vs. 132 cells/ $\mu$ L,  $p=0.039$ ), be non-ambulatory (56.9% vs. 35.7%,  $p=0.004$ ), have tachycardia (28.6% vs. 9.3%,  $p<0.001$ ) and have  $\geq 1$  WHO danger sign(s) of severe illness (70.8% vs. 56.4%  $p=0.044$ ) (Table 1). In multivariable analysis, only younger age (aOR=0.64, 95% CI=0.42-0.97,  $p=0.04$ ), chest pain  $>2$  weeks (aOR=3.32, 95% CI=1.38-8.02,  $p=0.007$ ), severe weight loss  $\geq 5$  kilograms (aOR=4.88, 95% CI=1.66-14.29,  $p=0.004$ ) and presence of  $\geq 1$  WHO severe illness danger sign (aOR=3.55, 95% CI=1.36-9.29,  $p=0.010$ ) remained independently associated with late recurrent TB. Inclusion of HIV infection, stratified or not by CD4 count, in the model did not alter the final effect estimates (Table 2).

### Treatment of late recurrent TB

Among the 84 patients with culture-confirmed late recurrent TB, 72 (85.7%) were initiated on anti-TB treatment; 67 (79.8%) were initiated before hospital discharge based on smear or Xpert MTB/RIF testing (52 on Category I treatment regimen – rifampicin, isoniazid, ethambutol and pyrazinamide, and 15 on Category II treatment regimen – streptomycin plus category I regimen).<sup>[26]</sup> Five (5.9%) confirmed treatment initiation after hospital discharge but were uncertain of the regimen. For reasons that were unknown, 12 (14.3%) patients did not initiate treatment by two months following diagnosis.

### Mortality of patients with late recurrent TB

Of the 84 patients with culture-confirmed late recurrent TB, 56 (66%) were alive, 15 (18%) were lost to follow-up and 13 (16%) had died 60 days following enrollment. Among the 69 patients for whom vital status could be confirmed, the cumulative incidence of 2-month mortality was 17.8% (95% CI=10.5-29.2). Among the 13 patients who died, 69% ( $n=9$ ) had initiated anti-TB treatment – 5 on category I, 3 on category II re-treatment, 1 on an unknown TB treatment regimen – and 4 received antibiotics but no anti-TB treatment. In addition, nine of the 13 (69%) patients who died were HIV sero-positive and had a median CD4 count 20 cells/ $\mu$ L (IQR: 9-47); only two of nine (22%) were on ART at study enrollment.

In multivariable analysis, 2-month hazard of mortality was increased among patients who had not initiated TB treatment (aHR=16.67, 95% CI=1.18-200,  $p=0.04$ ), HIV co-infected patients not on ART (aHR=16.99, 95% CI=1.17-246.47,  $p=0.04$ ) and patients with one pack-year history of smoking (aHR=1.20, 95% CI=1.03-1.40,  $p=0.02$ ) (Table 3). Early anti-TB treatment and ART improved survival (Figs 2 and 3). Patients with  $\geq 1$  WHO severe illness danger signs (aHR=5.92, 95% CI=0.73-48.03,  $p=0.096$ ) also had increased 2-month mortality, although this did not reach pre-specified statistical significance.

## Discussion

We found that among Ugandan patients who were hospitalised with symptoms of pneumonia and who had completed TB treatment at least 2 years earlier, 36% had culture-confirmed late recurrent TB. Xpert testing was ~10% more sensitive than smear microscopy but missed ~20% of patients with culture-confirmed late recurrent TB. Patients with late recurrent TB had high short-term mortality (17.8%); the mortality rate was increased among those who had not initiated anti-TB treatment and, if HIV-infected, were not on ART. These findings highlight the high transmission rate of TB and support empirical TB treatment initiation (and early ART, if HIV positive) in patients with a remote history of prior TB and recurrent TB symptoms.

Our findings are similar to previous cohort studies from East Africa assessing the prevalence of late recurrent TB. In a large population-based cohort study of TB patients actively followed up between 1996 and 2010 in northern rural Malawi, recurrent TB developed in 41 (42%) of 98 participants who had completed TB treatment >2 years earlier.<sup>[9]</sup> In a Phase 3 vaccine trial that enrolled and prospectively followed up HIV-infected adults in Tanzania for > 5 years, TB (defined as one or more positive smear or culture results) was diagnosed in 11 of 80 participants (13.8%), at a median of 108.3 months after prior active TB.<sup>[27]</sup> A molecular genotyping study attributed 76% of recurrent episodes to reinfection.<sup>[28]</sup> As other studies have shown that the majority of recurrent TB occurring two or more years after prior treatment completion is due to reinfection,<sup>[4, 9]</sup> we can assume that the majority of cases in our study were a result of acquiring a new *M. tuberculosis* strain, even though molecular genotyping was not performed. The recent National Tuberculosis Prevalence Survey, which found that TB prevalence was nearly 2-fold higher than previously reported, indicates that TB transmission remains high in Uganda.<sup>[29]</sup> Thus, our findings support the recently revised Uganda National Strategic Plan's emphasis on enhancing case detection, through systematic screening of high-risk groups, improved utilization of current diagnostic tools, addressing key barriers in health seeking behavior, enhanced involvement of the private sector, and stepping up community engagement.<sup>[30]</sup>

More accurate diagnostics are essential to enhanced case finding. Xpert had higher sensitivity than smear microscopy, 78.6% (95% CI 68.3-86.8) vs. 65.8% (95% CI 54.3-76.1). However, of 66 patients who received Xpert testing in real-time and had positive results, initiation of same-day treatment was missed for 7 (11%); 4 (6%) initiated TB treatment after hospital discharge and 3 (5%) did not initiate treatment during the two-month follow-up period. Xpert specificity (96.5%) in this study was lower than that reported in a large meta-analysis,<sup>[31]</sup> but is consistent with more recent studies of Xpert testing in populations with a prior history of TB.<sup>[32]</sup> Nonetheless, the positive predictive value was high (93.0%, 95% CI, 84.3%, 97.7%) given the high prevalence of recurrent TB in our population. Only 3% of our patients had RIF resistance identified by Xpert testing, which further supports reinfection, rather than relapse, as the reason for recurrent TB in the majority of patients.

Our data support the increased use of empirical treatment among hospitalised patients with a remote history of TB and symptoms suggesting recurrent TB disease, particularly when they

are HIV positive and diagnostics such as Xpert are not available. To help clinicians prioritize which patients should be treated empirically, we explored clinical characteristics associated with culture-confirmed late recurrent TB. We found that patients who had severe weight loss, chest pain for two or more weeks, and or at least one of the WHO severe illness danger signs were more likely to have late recurrent disease. It was noteworthy that these findings were consistent with a WHO recommendation regarding empirical TB treatment in patients with 1 WHO severe illness danger signs. Increased use of empiric treatment is particularly important given our finding that mortality was high in hospitalized patients with late recurrent TB, and earlier initiation of TB treatment appeared to reduce mortality.

A key strength of our study is that recurrent TB diagnosis was based on culture results rather than smear microscopy or Xpert MTB/RIF, which are both known to yield false-positive results due to identification of dead bacilli. Our study also had several potential limitations. Prevalence estimates from patients hospitalized at a referral facility are always likely to be higher than in the general population. Even so, our findings are similar to those reported from cohort studies in Malawi and Tanzania.<sup>[9, 27]</sup> Because our study was based on a secondary data analysis, we were limited to the data that had already been collected. As a result, we did not have information on factors that have been shown to predict recurrence, such as residual cavitary lesions, or information on drug adherence or anti-TB regimen taken during the prior episode of disease.

## Conclusions and implications

Late recurrent TB was common among hospitalized patients in Uganda but was often missed by currently available rapid diagnostics. Short-term mortality was high, but reduced among those who initiated anti-TB treatment promptly, or who started ART if HIV infected. These data support early empiric treatment when Xpert testing is not available or is negative, particularly in HIV-infected patients with severe weight loss >5 kilograms, chest pain >2 weeks, 1 WHO severe illness danger signs. Future studies should compare outcomes of patients with presumed recurrent TB when empiric treatment is provided based on the algorithm proposed here vs. routine care.

## Acknowledgments

We would like to thank the Mulago Hospital administration, healthcare providers, and patients for their support and participation in the study. We also would like to thank the staff and administration of the Infectious Diseases Research Collaboration and the Uganda National TB Reference Laboratory (NTRL) for making this study possible. The research was supported by the Training in Clinical Research program at University of California San Francisco, that was made possible by Fogarty International Center of the National Institutes of Health under the Award Number D43 TW010037 as well as NIH K24HL087713 (LH), R01HL090335 (LH), K23HL094141 (AC), K23AI080147 (JLD), R21AI101714 (JLD), K12 HL090147-04 (NDW), and U2RTW0006879 (COHRE). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## References

1. Zignol M, Wright A, Jaramillo E, Nunn P, Raviglione MC. Patients with previously treated tuberculosis no longer neglected. *Clinical infectious diseases*. 2007; 44(1):61–4. <https://doi.org/10.1086/509328>. [PubMed: 17143816]

2. Panjabi R, Comstock G, Golub J. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. *The International Journal of Tuberculosis and Lung Disease (IJTLD)*. The Union. Health Solutions for the poor. 2007; 11(8):828–37. [Review Article]. <http://www.ingentaconnect.com/content/iatld/ijtld/2007/00000011/00000008/art00002>.
3. Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? *Lancet Infect Dis*. 2003; 3 [http://dx.doi.org/10.1016/S1473-3099\(03\)00607-8](http://dx.doi.org/10.1016/S1473-3099(03)00607-8).
4. Chaisson RE, Churchyard GJ. Recurrent Tuberculosis: Relapse, Reinfection, and HIV. *The Journal of Infectious Diseases*. 2010; 201(5):653–5. <http://dx.doi.org/10.1086/650531>. [PubMed: 20121432]
5. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. *N Engl J Med*. 1994; 330(17): 1179–84. <http://dx.doi.org/10.1056/nejm199404283301702>. [PubMed: 8139628]
6. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. *J Infect Dis*. 2010; 201 <http://dx.doi.org/10.1086/650529>.
7. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. *J Infect Dis*. 2010; 201 <http://dx.doi.org/10.1086/650528>.
8. Luzze H, Johnson DF, Dickman K, Mayanja-Kizza H, Okwera A, Eisenach K, et al. Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease*. 2013; 17 <http://dx.doi.org/10.5588/ijtld.11.0692>.
9. Guerra-Assunção JA, Houben RMGJ, Crampin AC, Mzembe T, Mallard K, Coll F, et al. Recurrence due to Relapse or Reinfection With Mycobacterium tuberculosis: A Whole-Genome Sequencing Approach in a Large, Population-Based Cohort With a High HIV Infection Prevalence and Active Follow-up. *The Journal of Infectious Diseases*. 2015; 211(7):1154–63. <http://dx.doi.org/10.7554/elife.05166>. [PubMed: 25336729]
10. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, et al. Exogenous Reinfection as a Cause of Recurrent Tuberculosis after Curative Treatment. *New Engl Journal of Medicine*. 1999; 341(16):1174–9. <http://www.nejm.org/doi/full/10.1056/NEJM199910143411602>.
11. Marx FM, Dunbar R, Enarson DA, Williams BG, Warren RM, van der Spuy GD, et al. The Temporal Dynamics of Relapse and Reinfection Tuberculosis After Successful Treatment: A Retrospective Cohort Study. *Clinical Infectious Diseases*. 2014; 58(12):1676–83. <http://dx.doi.org/10.1093/cid/ciu186>. [PubMed: 24647020]
12. Bark CM, Furin JJ, Johnson JL. Approaches to clinical trials of new anti-TB drugs. *Clinical Investigation*. 2012; 2(4):359–70. <http://dx.doi.org/10.4155/cli.12.22>.
13. Kyeyune R, den Boon S, Cattamanchi A, Davis JL, Worodria W, Yoo SD, et al. Causes of Early Mortality in HIV-Infected TB Suspects in an East African Referral Hospital. *Journal of acquired-immune-deficiency-syndromes(1999)*. 2010; 55(4):446–50. <http://dx.doi.org/10.1097/qai.0b013e3181eb611a>. [PubMed: 21105258]
14. Cattamanchi A, Huang L, Worodria W, Boon Sd, Kalema N, Katagira W, et al. Integrated Strategies to Optimize Sputum Smear Microscopy. *American Journal of Respiratory and Critical Care Medicine*. 2011; 183(4):547–51. <http://dx.doi.org/10.1164/rccm.201008-1207oc>. [PubMed: 20851925]
15. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, Kalema N, et al. Impact of Xpert MTB/RIF Testing on Tuberculosis Management and Outcomes in Hospitalized Patients in Uganda. *PLoS ONE*. 2012; 7(11):e48599. <http://dx.doi.org/10.1371/journal.pone.0048599>. [PubMed: 23139799]
16. B, Michael N., K, A., Madhukar, P., et al. Risk of Tuberculosis from exposure to Tobacco smoke. 2007; 167:335–42. <http://dx.doi.org/10.1001/archinte.167.4.335>.
17. Picon PD, Bassanesi SL, Caramori ML, Ferreira RL, Jarczewski CA, Vieira PR. Risk factors for recurrence of tuberculosis. *J Bras Pneumol*. 2007; 33 <http://dx.doi.org/10.1590/S1806-37132007000500013>.

18. Yen YF, Yen MY, Lin YS, Lin YP, Shih HC, Li LH, et al. Smoking increases risk of recurrence after successful anti-tuberculosis treatment: a population-based study. *The International Journal of Tuberculosis and Lung Disease*. 2014; 18(4):492–8. <http://dx.doi.org/10.5588/ijtld.13.0694>. [PubMed: 24670708]
19. World Health Organization. Recommendations for HIV-Prevalent and Resource-Constrained Settings. Geneva, Switzerland: World Health Organization; 2007. Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extra-Pulmonary Tuberculosis among Adults and Adolescents. WHO/HTM/2007.379 & WHO/HIV/2007.1
20. Domingos MP, Caiaffa WT, Colosimo EA. Mortality, TB/HIV co-infection, and treatment dropout: predictors of tuberculosis prognosis in Recife, Pernambuco State, Brazil. *Cadernos de saúde pública/Ministério da Saúde, Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública*. 2008; 24 <http://dx.doi.org/10.1590/s0102-311x2008000400020>.
21. Gajalakshmi V, Peto R, Kanaka TS, Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. *Lancet*. 2003; 362(9383):507–15. [http://dx.doi.org/10.1016/s0140-6736\(03\)14109-8](http://dx.doi.org/10.1016/s0140-6736(03)14109-8). [PubMed: 12932381]
22. Gupta PC, Pednekar MS, Parkin D, Sankaranarayanan R. Tobacco associated mortality in Mumbai (Bombay) India. Results of the Bombay Cohort Study. *International Journal of Epidemiology*. 2005; 34(6):1395–402. <http://dx.doi.org/10.1093/ije/dyi196>. [PubMed: 16249218]
23. Worodria W, Massinga-Loembe M, Mazakpwe D, Luzinda K, Menten J, Van Leth F, et al. Incidence and Predictors of Mortality and the Effect of Tuberculosis Immune Reconstitution Inflammatory Syndrome in a Cohort of TB/HIV Patients Commencing Antiretroviral Therapy. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2011; 58(1):32–7. <http://dx.doi.org/10.1097/qai.0b013e3182255dc2>. [PubMed: 21654499]
24. Jacob ST, Moore CC, Banura P, Pinkerton R, Meya D, Opendi P, et al. Severe Sepsis in Two Ugandan Hospitals: a Prospective Observational Study of Management and Outcomes in a Predominantly HIV-1 Infected- Population. *PLoS ONE Journal*. 2009; 4(11):e7782. <http://dx.doi.org/10.1371/journal.pone.0007782>.
25. Pencina MJ, D'Agostino RB Sr. Evaluating discrimination of risk prediction models: The c-statistic. *JAMA*. 2015; 314(10):1063–4. <http://dx.doi.org/10.1001/jama.2015.11082>. [PubMed: 26348755]
26. World Health Organization. Treatment of Tuberculosis: Guidelines. Fourth Edition. Geneva, Switzerland: World Health Organization; 2010. SBN: 9789241547833; WHO/HTM/TB/2009.42, <http://www.who.int/tb/publications/2010/9789241547833/en/>
27. Lahey T, MacKenzie T, Arbeit RD, Bakari M, Mtei L, Matee M, et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. *Clinical infectious diseases*. 2013; 56(1):151–8. <http://dx.doi.org/10.1093/cid/cis798>. [PubMed: 22972862]
28. Adams LV, Kreiswirth BN, Arbeit RD, Soini H, Mtei L, Matee M, et al. Molecular Epidemiology of HIV-Associated Tuberculosis in Dar es Salaam, Tanzania: Strain Predominance, Clustering, and Polyclonal Disease. *Journal of Clinical Microbiology*. 2012; 50(8):2645–50. <http://dx.doi.org/10.1128/jcm.00624-12>. [PubMed: 22649022]
29. World-Health-Organization. Global-Tuberculosis-Report. 2016. <http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1>
30. World Health Organization. <http://www.afro.who.int/news/ministry-health-and-partners-review-national-tb-prevalence-survey-report>
31. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *The Cochrane Library*. *Cochrane Database Syst Rev*. 2013 Jan; 31(1):1–131. <http://dx.doi.org/10.1002/14651858.cd009593.pub3>.
32. Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, et al. Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results? *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2016; 62(8):995–1001. <http://dx.doi.org/10.1093/cid/civ1223>. [PubMed: 26908793]






Figure 1.  
STUDY POPULATION FLOW CHART



Number at risk		Time (days)						
		0	10	20	30	40	50	60
No TB treatment	11	9	8	8	8	8	8	8
Initiated TB treatment	57	54	52	50	50	49	45	

**Figure 2.**  
Kaplan Meier log-rank survival curve by TB treatment initiation



**Figure 3.**  
Kaplan Meier log-rank survival curve by ART initiation

**Table 1**

Baseline characteristics of the study population and association with recurrent pulmonary tuberculosis, Uganda (2008-2013)

Characteristics	All N=234	No Recurrent TB N=150 (64%)	Recurrent TB N=84 (36%)	p-value
	n (%)	n (%)	n (%)	
Age, years, median (IQR)	36.9 (30.8-44.2)	38.1 (31.9-46.2)	34.4 (29.5-39.9)	0.083
Male	137 (58.6)	85 (56.7)	52 (61.9)	0.435
Smoking ( > 100 cigarettes, lifetime)	77 (32.9)	48 (32.0)	29 (34.5)	0.693
Among ever smoked, pack yrs, median (IQR)	3.9 (1.5-8.4)	4.1 (1.5-8.4)	3.8 (1.2-6.4)	0.660
HIV sero-positive	161 (68.8)	102 (68.0)	59 (70.2)	0.723
Median CD4 count cells/uL (IQR)	119 (22-304)	132 (23-308)	70 (20-295)	0.039
On ART at admission (N=161)	75 (46.6)	50 (49.0)	25 (42.4)	0.415
Median years on ART (IQR)	3.2 (0.8-5.1)	3.7(0.9-5.7)	1.7(0.5-4.3)	0.191
Weight loss > 5kgs (N=212) *	134 (63.2)	73 (55.7)	61 (75.3)	0.004
Chest pain >2 weeks (N=170) *	96 (56.5)	52 (46.0)	44 (77.2)	< 0.001
WHO danger signs				
Non-ambulatory, (N=198) *	86 (43.4)	45 (35.7)	41 (56.9)	0.004
Temperature > 39° Celsius	9 (3.9)	4 (2.7)	5 (6.0)	0.210
Respiratory rate >30 breaths/min	100 (42.7)	63 (42.0)	37 (44.1)	0.761
Heart rate, > 120 beats/min	38 (16.2)	14 (9.3)	24 (28.6)	< 0.001
WHO danger signs	N=198	(N=140)	N=76	
0	76 (38.4)	55 (43.7)	21 (29.2)	
1	122 (61.6)	71 (56.4)	51 (70.8)	0.044

\* Missing data

**Table 2**  
Predictors of recurrent pulmonary TB among patients admitted with suspected pneumonia

Characteristic	Unadjusted OR (95% CI) N= 234	p-value	Adjusted OR (95% CI) N=133	p-value
Age, decades	0.70 (0.54-0.92)	0.011	0.64 (0.42-0.97)	0.035
HIV sero-positive	1.11 (0.62-1.98)	0.723		
Chest pain, >2 weeks (N=170) *	3.97 (1.93-8.16)	< 0.001	3.32 (1.38-8.02)	0.007
Weight loss 5kg (N=212) *	2.42 (1.31-4.47)	0.005	4.88 (1.66-14.3)	0.004
WHO danger signs				
Non-ambulatory (N=198) *	2.38 (1.32-4.30)	0.004		
Temperature > 39 C	2.31 (0.60-8.85)	0.222		
Respiratory rate > 30	1.09 (0.63-1.86)	0.761		
Heart rate > 120	3.89 (1.88-8.03)	< 0.001		
WHO danger signs				
0	Ref		Ref	
1-4	1.88 (1.01-3.49)	0.045	3.55 (1.36-9.29)	0.010

\* Missing data

**Table 3**  
Factors associated with two-month mortality among patients with recurrent pulmonary TB<sup>/</sup>

Characteristic	Unadjusted HR (95% CI) N=68		Adjusted HR (95% CI) N=57	
	HR	(95% CI)	aHR	(95% CI)
Age, years	0.99	(0.95-1.05)		
Male	1.91	(0.52-7.04)		
Packyears	1.03	(0.94-1.12)	1.20	(1.03-1.40)
Chestpain > 2 weeks (N=45)	2.13	(0.27-16.86)		0.018
Weight loss 5kg (N=65)	1.46	(0.32-6.67)		0.624
WHO danger sign category (N=57)				
0	Ref		Ref	
1-4	5.10	(0.64-39.95)	5.92	(0.73-48.03)
Missed TB treatment initiation	2.94	(0.89-10.00)	16.67	(1.18-200)
ART treatment initiated				0.037
HIV uninfected	Ref		Ref	
HIV infected, on ART	0.41	(0.07-2.45)	0.25	(0.02-3.75)
HIV infected – No ART	2.22	(0.57-8.57)	16.99	(1.17-246.47)

<sup>/</sup> Conditional total effect of TB treatment initiation or non-initiation (primary or main exposure of interest) on 60-day mortality - the causal effect of interest in the analysis, and the controlled direct effect estimates of confounders (covariates) in final fit model, namely; cigarette smoking in packyears, HIV infection on ART versus not on ART, and presence of WHO danger signs of severe illness.